Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Patient-reported Outcomes
100%
Minimal Clinically Important Difference
100%
Psoriatic Arthritis
100%
Risankizumab
100%
Placebo
60%
Disease Activity Score
30%
Patient Global Assessment
30%
Short Form 36 (SF-36)
20%
Work Activity
20%
Activity Impairment
20%
Work Productivity Impairment
20%
KEEPsAKE 2
20%
Odds Ratio
10%
Randomized Placebo-controlled Trial
10%
Quality of Life
10%
Adult Patients
10%
Intolerance
10%
Logistic Regression
10%
Patient Assessment
10%
Health Assessment Questionnaire Disability Index (HAQ-DI)
10%
Pain Assessment
10%
Chronic Inflammatory Diseases
10%
Disease-modifying Antirheumatic Drugs (DMARDs)
10%
Lack of Response
10%
Phase I Trial
10%
EQ-5D
10%
Presenteeism
10%
Baseline Factors
10%
Mental Component Summary Scores
10%
Physical Component Summary
10%
Stratification Parameter
10%
Functional Assessment of Chronic Illness Therapy-fatigue
10%
Clinically Meaningful Improvement
10%
Control Phase
10%
5-level EQ-5D
10%
Medicine and Dentistry
Minimal Clinically Important Difference
100%
Psoriatic Arthritis
100%
Risankizumab
100%
Patient-Reported Outcome
100%
Placebo
70%
Disease Activity
30%
Short Form 36
20%
Quality of Life
10%
Logistic Regression Analysis
10%
Patient Assessment
10%
Health Assessment Questionnaire
10%
Inflammatory Disorder
10%
Clinical Study
10%
Chronic Disease
10%
Functional Assessment
10%
Biological Product
10%
Disease Modifying Antirheumatic Drug
10%
Odds Ratio
10%
Nursing and Health Professions
Patient-Reported Outcome
100%
Minimal Clinically Important Difference
100%
Psoriatic Arthritis
100%
Risankizumab
100%
Placebo
70%
Disease Activity
30%
Short Form 36
20%
Odds Ratio
10%
Health Assessment Questionnaire
10%
Inflammatory Disease
10%
Logistic Regression Analysis
10%
Chronic Disease
10%
Biological Product
10%
Patient Assessment
10%
Functional Assessment
10%
Disease Modifying Antirheumatic Drug
10%
Quality of Life
10%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriatic Arthritis
100%
Risankizumab
100%
Placebo
70%
Disease Activity
30%
Inflammatory Disease
10%
Clinical Study
10%
Chronic Disease
10%
Biological Product
10%
Disease Modifying Antirheumatic Drug
10%